Cortec Achieves German BCI Milestone: First Human Brain Implant
CorTec GmbH has implanted its Brain Interchange™ brain-computer interface (BCI) system in a human for the first time. The...
Therini Doses First Patient in Alzheimer’s Trial
Therini Bio has dosed the first patient in a Phase 1b trial of THN391, a monoclonal antibody targeting the...
Vivex Completes Subject Enrollment for Ascend Trial of Via Disc NP
Vivex Biologics has completed enrollment in its ASCEND trial of VIA Disc NP for symptomatic degenerative disc disease (DDD)....
EyePoint Completes Duravyu™ Phase 3 Wet AMD Trial Enrollment
EyePoint Pharmaceuticals has completed enrollment in its Phase 3 LUCIA trial of DURAVYU (vorolanib intravitreal insert) for wet age-related...
Pharmazz Inc. Begins Phase 3 Sovateltide Trial for Stroke
Pharmazz has initiated its pivotal Phase 3 RESPECT-ETB trial evaluating sovateltide, a first-in-class endothelin-B receptor agonist, in acute cerebral...
Fulcrum Therapeutics Announces Results from Phase 1b Pioneer Trial of Pociredir in Sickle Cell Disease
Fulcrum Therapeutics reported positive 12-week data from the 12mg dose cohort of its Phase 1b PIONEER trial of pociredir...
Brincidofovir: Potential Antiviral for Mpox Treatment
Emergent BioSolutions announced the publication of a review article on the use of its investigational antiviral drug, brincidofovir, for...
NetraMark & Algotx Join Forces to Optimize Atx01 Clinical Trials
NetraMark Holdings Inc., an AI company specializing in clinical trials, and AlgoTherapeutix SAS (AlgoTx), a biotech company developing therapies...
Radiopharm B7-H3 BetaBart RV-01 IND Approved for Phase 1 Study
Radiopharm Theranostics has received FDA Investigational New Drug (IND) application clearance for Betabart (RV-01), a Lu177-B7H3 monoclonal antibody targeting...
FDA Approves BMD as Primary Endpoint for EB613 Osteoporosis Study
Entera Bio received positive feedback from the FDA regarding its New Drug Application (NDA) for EB613, an oral treatment...